DXCM Stock — DexCom Inc.

DexCom Inc. (DXCM)

Updated October 16, 2026.

DXCM is a Stock. Total return is 2831.5% over the past 21.5 years, 1955.8 points ahead of SPY at 875.7%.

DexCom is a medical device company that designs, develops, and commercializes continuous glucose monitoring systems for diabetes and metabolic health management, marketing its products including the Dexcom G7 and G6 systems directly to healthcare providers in the U.S. and internationally. The company does not currently distribute dividends to shareholders. DexCom appeals to growth-oriented investors seeking exposure to the medical device and diabetes care sectors.

DXCM performance versus SPY

Price and return data through 2026-10-16.

Total return is 2831.5% over the past 21.5 years, 1955.8 points ahead of SPY at 875.7%. Over the past year its total return — price change plus distributions reinvested — is 29.7%. Its deepest 1-year drawdown was 22.8%.

DXCM key facts

Asset type

Stock

Asset class

Equity

Inception date

04/14/2005

Distribution frequency

None

Last close

$86.04 (as of 2026-10-16)

Market cap

$32,468,120,221

Average volume

3500493.0

Beta

1.477

Payout ratio

0.0%

P/E ratio

34.14

Forward P/E

28.2486

EPS

$2.52

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

DXCM risks and drawbacks

The deepest 1-year drawdown on record here is 22.8%.

Who may consider DXCM — and who may not

It is a weaker fit for investors who need monthly cash flow (DXCM does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on DXCM

• All tickers starting with D

Tagged: Healthcare.

Frequently asked questions